Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 213

1.

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.

Guan J, Fransson S, Siaw JT, Treis D, Van den Eynden J, Chand D, Umapathy G, Ruuth K, Svenberg P, Wessman S, Shamikh A, Jacobsson H, Gordon L, Stenman J, Svensson PJ, Hansson M, Larsson E, Martinsson T, Palmer RH, Kogner P, Hallberg B.

Cold Spring Harb Mol Case Stud. 2018 Aug 1;4(4). pii: a002550. doi: 10.1101/mcs.a002550. Print 2018 Aug.

2.

Sense-Antisense lncRNA Pair Encoded by Locus 6p22.3 Determines Neuroblastoma Susceptibility via the USP36-CHD7-SOX9 Regulatory Axis.

Mondal T, Juvvuna PK, Kirkeby A, Mitra S, Kosalai ST, Traxler L, Hertwig F, Wernig-Zorc S, Miranda C, Deland L, Volland R, Bartenhagen C, Bartsch D, Bandaru S, Engesser A, Subhash S, Martinsson T, Carén H, Akyürek LM, Kurian L, Kanduri M, Huarte M, Kogner P, Fischer M, Kanduri C.

Cancer Cell. 2018 Mar 12;33(3):417-434.e7. doi: 10.1016/j.ccell.2018.01.020.

PMID:
29533783
3.

MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.

Umapathy G, Guan J, Gustafsson DE, Javanmardi N, Cervantes-Madrid D, Djos A, Martinsson T, Palmer RH, Hallberg B.

Sci Signal. 2017 Nov 28;10(507). pii: eaam7550. doi: 10.1126/scisignal.aam7550.

PMID:
29184034
4.

Correction: A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.

Tomić TT, Olausson J, Wilzén A, Sabel M, Truvé K, Sjögren H, Dósa S, Tisell M, Lannering B, Enlund F, Martinsson T, Åman P, Abel F.

PLoS One. 2017 Sep 7;12(9):e0184715. doi: 10.1371/journal.pone.0184715. eCollection 2017.

5.

Rho-associated kinase is a therapeutic target in neuroblastoma.

Dyberg C, Fransson S, Andonova T, Sveinbjörnsson B, Lännerholm-Palm J, Olsen TK, Forsberg D, Herlenius E, Martinsson T, Brodin B, Kogner P, Johnsen JI, Wickström M.

Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):E6603-E6612. doi: 10.1073/pnas.1706011114. Epub 2017 Jul 24.

6.

A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.

Tomić TT, Olausson J, Wilzén A, Sabel M, Truvé K, Sjögren H, Dósa S, Tisell M, Lannering B, Enlund F, Martinsson T, Åman P, Abel F.

PLoS One. 2017 Apr 27;12(4):e0175638. doi: 10.1371/journal.pone.0175638. eCollection 2017. Erratum in: PLoS One. 2017 Sep 7;12 (9):e0184715.

7.

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.

Guan J, Tucker ER, Wan H, Chand D, Danielson LS, Ruuth K, El Wakil A, Witek B, Jamin Y, Umapathy G, Robinson SP, Johnson TW, Smeal T, Martinsson T, Chesler L, Palmer RH, Hallberg B.

Dis Model Mech. 2016 Sep 1;9(9):941-52. doi: 10.1242/dmm.024448. Epub 2016 Jul 7.

8.

The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.

Bogen D, Brunner C, Walder D, Ziegler A, Abbasi R, Ladenstein RL, Noguera R, Martinsson T, Amann G, Schilling FH, Ussowicz M, Benesch M, Ambros PF, Ambros IM.

Int J Cancer. 2016 Jul 1;139(1):153-63. doi: 10.1002/ijc.30050. Epub 2016 Mar 22.

9.

The 1p36 Tumor Suppressor KIF 1Bβ Is Required for Calcineurin Activation, Controlling Mitochondrial Fission and Apoptosis.

Li S, Fell SM, Surova O, Smedler E, Wallis K, Chen ZX, Hellman U, Johnsen JI, Martinsson T, Kenchappa RS, Uhlén P, Kogner P, Schlisio S.

Dev Cell. 2016 Jan 25;36(2):164-78. doi: 10.1016/j.devcel.2015.12.029.

10.

Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.

Fransson S, Östensson M, Djos A, Javanmardi N, Kogner P, Martinsson T.

Int J Oncol. 2016 Mar;48(3):1103-16. doi: 10.3892/ijo.2016.3349. Epub 2016 Jan 19.

PMID:
26794043
11.

Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors.

Olsson M, Beck S, Kogner P, Martinsson T, Carén H.

Epigenetics. 2016;11(1):74-84. doi: 10.1080/15592294.2016.1138195. Epub 2016 Jan 19.

12.

Exome Sequencing of an Adult Pituitary Atypical Teratoid Rhabdoid Tumor.

Biswas S, Wood M, Joshi A, Bown N, Strain L, Martinsson T, Campbell J, Ashworth A, Swain A.

Front Oncol. 2015 Oct 23;5:236. doi: 10.3389/fonc.2015.00236. eCollection 2015.

13.

Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.

Berbegall AP, Villamón E, Piqueras M, Tadeo I, Djos A, Ambros PF, Martinsson T, Ambros IM, Cañete A, Castel V, Navarro S, Noguera R.

Oncogene. 2016 Mar 17;35(11):1423-32. doi: 10.1038/onc.2015.200. Epub 2015 Jun 29.

PMID:
26119945
14.

COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset.

Larsson K, Kock A, Idborg H, Arsenian Henriksson M, Martinsson T, Johnsen JI, Korotkova M, Kogner P, Jakobsson PJ.

Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):8070-5. doi: 10.1073/pnas.1424355112. Epub 2015 Jun 15.

15.

The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation.

Pandey GK, Mitra S, Subhash S, Hertwig F, Kanduri M, Mishra K, Fransson S, Ganeshram A, Mondal T, Bandaru S, Ostensson M, Akyürek LM, Abrahamsson J, Pfeifer S, Larsson E, Shi L, Peng Z, Fischer M, Martinsson T, Hedborg F, Kogner P, Kanduri C.

Cancer Cell. 2014 Nov 10;26(5):722-37. doi: 10.1016/j.ccell.2014.09.014. Epub 2014 Nov 10.

16.

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.

Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, Bénard J, Berbegall AP, Bown N, Combaret V, Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, Valent A, Van Roy N, Vicha A, Villamon E, Tonini GP.

Br J Cancer. 2015 Jan 20;112(2):290-5. doi: 10.1038/bjc.2014.557. Epub 2014 Nov 4.

17.

Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.

Fransson S, Hansson M, Ruuth K, Djos A, Berbegall A, Javanmardi N, Abrahamsson J, Palmer RH, Noguera R, Hallberg B, Kogner P, Martinsson T.

Genes Chromosomes Cancer. 2015 Feb;54(2):99-109. doi: 10.1002/gcc.22223. Epub 2014 Sep 23.

PMID:
25251827
18.

Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltration.

Berbegall AP, Villamón E, Tadeo I, Martinsson T, Cañete A, Castel V, Navarro S, Noguera R.

Neoplasia. 2014 Jun;16(6):471-80. doi: 10.1016/j.neo.2014.05.012.

19.

Emergence of new ALK mutations at relapse of neuroblastoma.

Schleiermacher G, Javanmardi N, Bernard V, Leroy Q, Cappo J, Rio Frio T, Pierron G, Lapouble E, Combaret V, Speleman F, de Wilde B, Djos A, Ora I, Hedborg F, Träger C, Holmqvist BM, Abrahamsson J, Peuchmaur M, Michon J, Janoueix-Lerosey I, Kogner P, Delattre O, Martinsson T.

J Clin Oncol. 2014 Sep 1;32(25):2727-34. doi: 10.1200/JCO.2013.54.0674. Epub 2014 Jul 28.

PMID:
25071110
20.

Deletion of the MGMT gene in familial melanoma.

Appelqvist F, Yhr M, Erlandson A, Martinsson T, Enerbäck C.

Genes Chromosomes Cancer. 2014 Aug;53(8):703-11. doi: 10.1002/gcc.22180. Epub 2014 May 6.

PMID:
24801985
21.

A mutation in POLE predisposing to a multi-tumour phenotype.

Rohlin A, Zagoras T, Nilsson S, Lundstam U, Wahlström J, Hultén L, Martinsson T, Karlsson GB, Nordling M.

Int J Oncol. 2014 Jul;45(1):77-81. doi: 10.3892/ijo.2014.2410. Epub 2014 Apr 29.

22.

Aneuploidy in neuroblastoma tumors is not associated with inactivating point mutations in the STAG2 gene.

Djos A, Fransson S, Kogner P, Martinsson T.

BMC Med Genet. 2013 Oct 2;14:102. doi: 10.1186/1471-2350-14-102.

23.

Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy.

Passariello A, De Brasi D, Defferrari R, Genesio R, Tufano M, Mazzocco K, Capasso M, Migliorati R, Martinsson T, Siani P, Nitsch L, Tonini GP.

Eur J Med Genet. 2013 Nov;56(11):626-34. doi: 10.1016/j.ejmg.2013.08.005. Epub 2013 Sep 13.

PMID:
24035971
24.

The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes.

Carlson LM, De Geer A, Sveinbjørnsson B, Orrego A, Martinsson T, Kogner P, Levitskaya J.

Oncoimmunology. 2013 Mar 1;2(3):e23618.

25.

Frequent detection of human cytomegalovirus in neuroblastoma: a novel therapeutic target?

Wolmer-Solberg N, Baryawno N, Rahbar A, Fuchs D, Odeberg J, Taher C, Wilhelmi V, Milosevic J, Mohammad AA, Martinsson T, Sveinbjörnsson B, Johnsen JI, Kogner P, Söderberg-Nauclér C.

Int J Cancer. 2013 Nov 15;133(10):2351-61. doi: 10.1002/ijc.28265. Epub 2013 Jul 13.

26.

Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.

Cetinkaya C, Martinsson T, Sandgren J, Träger C, Kogner P, Dumanski J, Díaz de Ståhl T, Hedborg F.

BMC Cancer. 2013 May 9;13:231. doi: 10.1186/1471-2407-13-231.

27.

Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas.

Fransson S, Kogner P, Martinsson T, Ejeskär K.

J Mol Signal. 2013 Apr 18;8(1):4. doi: 10.1186/1750-2187-8-4.

28.

Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.

Villamón E, Berbegall AP, Piqueras M, Tadeo I, Castel V, Djos A, Martinsson T, Navarro S, Noguera R.

PLoS One. 2013;8(1):e53740. doi: 10.1371/journal.pone.0053740. Epub 2013 Jan 14.

29.

Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.

Rasmuson A, Segerström L, Nethander M, Finnman J, Elfman LH, Javanmardi N, Nilsson S, Johnsen JI, Martinsson T, Kogner P.

PLoS One. 2012;7(12):e51297. doi: 10.1371/journal.pone.0051297. Epub 2012 Dec 17.

30.

Stage-dependent expression of PI3K/Akt‑pathway genes in neuroblastoma.

Fransson S, Abel F, Kogner P, Martinsson T, Ejeskär K.

Int J Oncol. 2013 Feb;42(2):609-16. doi: 10.3892/ijo.2012.1732. Epub 2012 Dec 12.

PMID:
23232578
31.

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.

Chand D, Yamazaki Y, Ruuth K, Schönherr C, Martinsson T, Kogner P, Attiyeh EF, Maris J, Morozova O, Marra MA, Ohira M, Nakagawara A, Sandström PE, Palmer RH, Hallberg B.

Dis Model Mech. 2013 Mar;6(2):373-82. doi: 10.1242/dmm.010348. Epub 2012 Oct 25.

32.

Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas.

Kiss NB, Kogner P, Johnsen JI, Martinsson T, Larsson C, Geli J.

BMC Med Genet. 2012 Sep 17;13:83. doi: 10.1186/1471-2350-13-83.

33.

The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.

Djos A, Martinsson T, Kogner P, Carén H.

Mol Cancer. 2012 Jun 13;11:40. doi: 10.1186/1476-4598-11-40.

34.

Hereditary myopathy with early respiratory failure associated with a mutation in A-band titin.

Ohlsson M, Hedberg C, Brådvik B, Lindberg C, Tajsharghi H, Danielsson O, Melberg A, Udd B, Martinsson T, Oldfors A.

Brain. 2012 Jun;135(Pt 6):1682-94. doi: 10.1093/brain/aws103. Epub 2012 May 9.

PMID:
22577218
35.

High-resolution copy number array in the molecular cytogenetic diagnostics of pediatric malignant hematological disorders.

Wikhager C, Ögärd I, Martinsson T, Abrahamsson J, Palmqvist L, Sjögren H.

Oncol Rep. 2012 May;27(5):1429-34. doi: 10.3892/or.2012.1689. Epub 2012 Feb 16.

PMID:
22344473
36.

Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.

Schönherr C, Ruuth K, Kamaraj S, Wang CL, Yang HL, Combaret V, Djos A, Martinsson T, Christensen JG, Palmer RH, Hallberg B.

Oncogene. 2012 Dec 13;31(50):5193-200. doi: 10.1038/onc.2012.12. Epub 2012 Jan 30.

PMID:
22286764
37.

Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors.

Kryh H, Carén H, Erichsen J, Sjöberg RM, Abrahamsson J, Kogner P, Martinsson T.

BMC Genomics. 2011 Sep 7;12:443. doi: 10.1186/1471-2164-12-443.

38.

MYCN amplicon junctions as tumor-specific targets for minimal residual disease detection in neuroblastoma.

Kryh H, Abrahamsson J, Jegerås E, Sjöberg RM, Devenney I, Kogner P, Martinsson T.

Int J Oncol. 2011 Nov;39(5):1063-71. doi: 10.3892/ijo.2011.1120. Epub 2011 Jul 12.

PMID:
21750863
39.

MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma.

Haug BH, Henriksen JR, Buechner J, Geerts D, Tømte E, Kogner P, Martinsson T, Flægstad T, Sveinbjørnsson B, Einvik C.

Carcinogenesis. 2011 Jul;32(7):1005-12. doi: 10.1093/carcin/bgr073. Epub 2011 May 13.

PMID:
21572098
40.

A multilocus technique for risk evaluation of patients with neuroblastoma.

Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Bénard J, Bown N, Combaret V, Couturier J, Defferrari R, Gross N, Jeison M, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Speleman F, Stallings R, Tonini GP, Tweddle DA, Valent A, Vicha A, Roy NV, Villamon E, Ziegler A, Preuner S, Drobics M, Ladenstein R, Amann G, Schuit RJ, Pötschger U, Ambros PF.

Clin Cancer Res. 2011 Feb 15;17(4):792-804. doi: 10.1158/1078-0432.CCR-10-0830.

41.

Alternative lengthening of telomeres--an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas.

Lundberg G, Sehic D, Länsberg JK, Øra I, Frigyesi A, Castel V, Navarro S, Piqueras M, Martinsson T, Noguera R, Gisselsson D.

Genes Chromosomes Cancer. 2011 Apr;50(4):250-62. doi: 10.1002/gcc.20850. Epub 2011 Jan 14.

PMID:
21319260
42.

Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma.

Carén H, Djos A, Nethander M, Sjöberg RM, Kogner P, Enström C, Nilsson S, Martinsson T.

BMC Cancer. 2011 Feb 11;11:66. doi: 10.1186/1471-2407-11-66.

43.

Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.

Martinsson T, Eriksson T, Abrahamsson J, Caren H, Hansson M, Kogner P, Kamaraj S, Schönherr C, Weinmar J, Ruuth K, Palmer RH, Hallberg B.

Cancer Res. 2011 Jan 1;71(1):98-105. doi: 10.1158/0008-5472.CAN-10-2366. Epub 2010 Nov 8.

44.

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.

De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, De Paepe A, Laureys G, Schulte JH, Schramm A, Van Den Broecke C, Vermeulen J, Van Roy N, Beiske K, Renard M, Noguera R, Delattre O, Janoueix-Lerosey I, Kogner P, Martinsson T, Nakagawara A, Ohira M, Caron H, Eggert A, Cools J, Versteeg R, Speleman F.

Clin Cancer Res. 2010 Sep 1;16(17):4353-62. doi: 10.1158/1078-0432.CCR-09-2660. Epub 2010 Aug 18.

45.

Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.

Åsberg C, Hjalmarson O, Alm J, Martinsson T, Waldenström J, Hellerud C.

J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S113-21. doi: 10.1007/s10545-009-9034-5. Epub 2010 Feb 12.

PMID:
20151204
46.

High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset.

Carén H, Kryh H, Nethander M, Sjöberg RM, Träger C, Nilsson S, Abrahamsson J, Kogner P, Martinsson T.

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4323-8. doi: 10.1073/pnas.0910684107. Epub 2010 Feb 9.

47.

Germline mutation screening of the Saethre-Chotzen-associated genes TWIST1 and FGFR3 in families with BRCA1/2-negative breast cancer.

Bergman A, Sahlin P, Emanuelsson M, Carén H, Tarnow P, Martinsson T, Grönberg H, Stenman G.

Scand J Plast Reconstr Surg Hand Surg. 2009;43(5):251-5. doi: 10.3109/02844310903247228.

PMID:
19863427
48.

Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes.

Thorell K, Bergman A, Carén H, Nilsson S, Kogner P, Martinsson T, Abel F.

BMC Med Genomics. 2009 Aug 17;2:53. doi: 10.1186/1755-8794-2-53.

49.

The Phox2 pathway is differentially expressed in neuroblastoma tumors, but no mutations were found in the candidate tumor suppressor gene PHOX2A.

Wilzén A, Nilsson S, Sjöberg RM, Kogner P, Martinsson T, Abel F.

Int J Oncol. 2009 Mar;34(3):697-705.

PMID:
19212675
50.

Germline mutation in the FGFR3 gene in a TWIST1-negative family with Saethre-Chotzen syndrome and breast cancer.

Sahlin P, Tarnow P, Martinsson T, Stenman G.

Genes Chromosomes Cancer. 2009 Mar;48(3):285-8. doi: 10.1002/gcc.20637. No abstract available.

PMID:
19025794

Supplemental Content

Loading ...
Support Center